Delivery Order SPE2DB24D1006-SPE2DB25FCEXB
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for XYOSTED 75 mg/0.5 ml auto-injector pharmaceutical supplies, valued at $1,865.12 with a firm fixed price contract type. The order was competitively awarded without set-aside provisions and is scheduled for completion by September 4, 2025, with fulfillment based at the vendor's Conshohocken, Pennsylvania location. This delivery order represents a routine pharmaceutical procurement supporting federal medical...
- The Defense Logistics Agency awarded a $2,155.28 firm fixed price delivery order to AmerisourceBergen Drug Corp for XYOSTED 100 MG/0.5 ML auto-injector vials on August 11, 2025, with completion targeted for August 12, 2025. This non-set-aside contract will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a single transaction fulfilling immediate pharmaceutical supply requirements within the federal medical procurement system....
- The Defense Logistics Agency awarded a delivery order valued at $1,655.80 to AmerisourceBergen Drug Corp for XYOSTED 75 mg/0.5 mL auto-injector units on July 28, 2025, with completion expected by July 29, 2025. This delivery order represents a firm fixed-price purchase with no set-aside designation, indicating the award was made through open competition. The pharmaceutical product will be delivered to the place of performance located in Conshohocken, Pennsylvania, where AmerisourceBergen...
- The Defense Logistics Agency awarded a $1,494.88 delivery order to AmerisourceBergen Drug Corp for XYOSTED 50 mg/0.5 mL auto-injector supplies, with an ultimate completion date of June 20, 2025. This non-set-aside, firm fixed price delivery order was issued on June 18, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a continuation of the company's role as a critical pharmaceutical distributor for federal medical...
- The Defense Logistics Agency has awarded a delivery order valued at $1,067.72 to AmerisourceBergen Drug Corp for XYOSTED 100 MG/0.5 ML auto-injector pharmaceutical supplies. The contract is a firm fixed price delivery order with an ultimate completion date of June 3, 2025, and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. This award was made through open competition with no set-aside designation, reflecting AmerisourceBergen's demonstrated capability...
- The Defense Logistics Agency awarded a $3,155.07 delivery order to AmerisourceBergen Drug Corp for XYOSTED 75 mg/0.5 mL auto-injector medication, with performance scheduled for completion by July 22, 2025. This non-competitive delivery order represents a firm fixed price contract executed on July 21, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement...
- The Defense Logistics Agency awarded a delivery order valued at $1,150.15 to AmerisourceBergen Drug Corp for XYOSTED 75 mg/0.5 mL auto-injector supplies. The contract, which is non-set-aside and competitively awarded, was issued on August 1, 2025, with an ultimate completion date of August 4, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The delivery order operates under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for XYOSTED 100 MG/0.5 ML auto-injector supplies, valued at $1,375.14 under a firm fixed-price contract type. The award, issued on July 14, 2025, with a completion date of July 15, 2025, represents a non-set-aside competitive award. Performance will be executed at the contractor's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a $1,358.05 delivery order to AmerisourceBergen Drug Corp for XYOSTED 100 mg/0.5 mL auto-injector units. This non-set-aside contract is classified as a firm fixed price delivery order with an ultimate completion date of August 28, 2025, and was awarded on August 27, 2025. The pharmaceutical product will be delivered to the contractor's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite...
- The Defense Logistics Agency awarded a $2,665.27 delivery order to AmerisourceBergen Drug Corp for XYOSTED 100 mg/0.5 ml auto-injector supplies on September 16, 2025, with completion targeted for September 17, 2025. This firm fixed-price contract, which carries no set-aside designation, represents a competitively awarded order fulfilled from AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The product will be delivered to AmerisourceBergen's facility in...
- SPE2DB24D1006Indefinite Delivery Contract
- SPE2DB24D1006-SPE2DB25FCEXBDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,111.28 to AmerisourceBergen Drug Corp for XYOSTED 100 mg/0.5 ml auto-injector supplies. This competitively awarded, firm fixed-price delivery order was issued on July 17, 2025, with an ultimate completion date of July 18, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The contract represents a routine pharmaceutical procurement through the federal medical supply chain, with no set-aside designation applied. This delivery order is executed under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, a $999,999,999.00 comprehensive global pharmaceutical support vehicle running through December 2026. AmerisourceBergen serves as a critical pharmaceutical distributor for federal healthcare systems, including the Defense Health Agency and U.S. Coast Guard, supplying an extensive portfolio of brand-name and generic medications, specialty drugs, vaccines, and medical supplies across multiple therapeutic domains. The company's position as a prime vendor reflects its demonstrated capability to fulfill diverse federal medical procurement requirements through competitive procurement processes.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.1k | 7/17/25 |